Evidence map›Paper›PMID 39495254›Full record

ArticleCancer research2025

PHGDH Induction by MAPK Is Essential for Melanoma Formation and Creates an Actionable Metabolic Vulnerability.

Neel Jasani, Xiaonan Xu, Benjamin Posorske, Yumi Kim, Kaizhen Wang, Olga Vera, Kenneth Y Tsai, Gina M DeNicola, Florian A Karreth

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. PHGDH is a targetable driver of PDAC progression.bioRxiv : the preprint server for biology · 2026
    Article
  5. Review
  6. The Roles of PTEN in Melanoma Suppression.Pigment cell & melanoma research · 2025
    Review
  7. Metabolic Reprogramming in Melanoma: An Epigenetic Point of View.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Neel JasaniDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0003-1133-5554
Xiaonan XuDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-7366-580X
Benjamin PosorskeDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0009-0003-7022-5547
Yumi KimDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0001-8815-3121
Kaizhen WangDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0001-6033-7041
Olga VeraDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-1878-4945
Kenneth Y TsaiDepartment of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0001-5325-212X
Gina M DeNicolaDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0001-6611-6696
Florian A KarrethDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-2350-9809

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Project 4P01CA250984 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2021 to 2025
$10.1M
Targeting a PHGDH metabolic vulnerability in melanomaR21CA289213 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI KARRETH, FLORIAN · 2024 to 2024
$433k
Florida Department of Health (DOH) 21B04Harry J. Lloyd Charitable Trust (HJLCT) Career Development AwardMoffitt Cancer Center (MCC) Miles for MoffittNational Cancer Institute (NCI) P01CA250984NCI NIH HHS P01 CA250984NCI NIH HHS P30 CA076292NCI NIH HHS R21 CA289213
6 · The paper itself

Abstract

Overexpression of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in the serine synthesis pathway, promotes melanomagenesis, melanoma cell proliferation, and survival of metastases in serine-low environments such as the brain. Here, we found that PHGDH is universally increased in melanoma cells and required for melanomagenesis. Although PHGDH amplification explained PHGDH overexpression in a subset of melanomas, oncogenic BRAFV600E also promoted PHGDH transcription through mTORC1-mediated translation of ATF4. Importantly, depletion of PHGDH in genetic mouse melanoma models blocked tumor formation. In addition to BRAFV600E-mediated upregulation, PHGDH was further induced by exogenous serine restriction. Surprisingly, BRAFV600E inhibition diminished serine restriction-mediated PHGDH expression by preventing ATF4 induction. Consequently, melanoma cells could be specifically starved of serine by combining BRAFV600E inhibition with exogenous serine restriction, which promoted cell death in vitro and attenuated melanoma growth in vivo. In summary, this study identified that PHGDH is essential for melanomagenesis and regulated by BRAFV600E, revealing a targetable vulnerability in BRAFV600E-mutant melanoma. Significance: BRAFV600E promotes the expression of the serine synthesis enzyme PHGDH, which is required for melanoma formation, and can be targeted to sensitize melanoma to dietary serine restriction, providing a melanoma cell-specific treatment strategy.

Indexed as

MelanomaPhosphoglycerate DehydrogenaseSkin NeoplasmsActivating Transcription Factor 4AnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMechanistic Target of Rapamycin Complex 1MiceProto-Oncogene Proteins B-rafSerineActivating Transcription Factor 4BRAF protein, humanMechanistic Target of Rapamycin Complex 1Phosphoglycerate DehydrogenaseProto-Oncogene Proteins B-rafSerine

Identifiers

PMID39495254
PMCPMC11735329

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.